The first payment of peak 2013 corporate bonds is completed.
Release time:
2020-07-31
News from our newspaper 6# April 5 , Jianfeng Group 2013 Corporate Bond (Phase I) principal and interest payment was successfully completed.
2013 6 , approved by the China Securities Regulatory Commission, Jianfeng Group 2013 corporate bonds (Phase I) were publicly issued with an issue amount of RMB 3 billion. The issue is a 5 -year fixed rate bond with a coupon rate increase option and an investor resale option at the end of the third year, with a debt rating of AA +(up to AAA ). The coupon rate of the bonds was determined by market bidding and was finally determined as 4.90% , which was 1.55 percentage points lower than the benchmark interest rate of 5 -year bank loans at that time, fully reflecting the capital market's affirmation of Jianfeng Group. After the issuance of
Jianfeng Group's 2013 corporate bonds (the first issue), they were listed and traded on the Shanghai Stock Exchange on 7 September 2 of that year. As some investors chose to sell back at the end of the third year, the company paid the resale on 2016 6 May , reducing the bond balance to 2.77 .9 billion yuan. By the time the bonds mature, the total amount of principal and interest to be paid is 2.9 .1 billion yuan (including tax).
In order to do a good job in repaying the principal and interest of the bonds, the group company issued a public announcement on 5 25 , registered the relevant rights and interests, and entrusted China Securities Depository Shanghai Branch to pay and exchange interest on the bonds. 6 Month 5 , the maturity date of the bond, the principal and interest payment was successfully completed. Corporate bonds are securities issued by companies in the stock exchange market in accordance with legal procedures and agreed to repay the principal and interest within a certain period of time, and the issuance of corporate bonds is one of the main ways of direct financing. Bondholders are creditors of the company and have the right to obtain interest from the company and recover the principal at maturity on agreed terms, but do not participate in the company's operation, management and other activities. Once the bond matures, the company must repay the principal. Through the issuance of corporate bonds, not only can replace short-term borrowing, but also increase the company's working capital, is conducive to optimizing the company's debt structure, enhance the company's short-term solvency, control the company's cost of capital, so many enterprises become an important way of financing. However, with the gradual deepening of "deleveraging" since 2017
20 bonds have defaulted in 2018 , and the share prices of listed companies that broke out of the corporate debt crisis have all fallen sharply. Zhu Jianwei, secretary of the board of directors of Group Company, said that although there are many reasons for the emergence of the corporate debt crisis, in the final analysis, some enterprises with excessive expansion in the early stage and low development quality are in the general environment of monetary policy shift and increasing financing difficulties., The contradiction of lack of sufficient cash flow is prominent. The successful completion of the payment of the Peak 2013
Fu Yiwu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page